Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
about
Immune targeting of cancer stem cells in gastrointestinal oncologyRapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cellsCoronary artery calcifications predict long term cardiovascular events in non diabetic Caucasian hemodialysis patients.CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis.CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysisPrioritization schema for immunotherapy clinical trials in glioblastoma.Inflammatory and immune markers associated with physical frailty syndrome: findings from Singapore longitudinal aging studiesCAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most EffectiveIdentification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens.Engineered T cells: the promise and challenges of cancer immunotherapy.Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis.Mitochondrial Priming by CD28.Are ovarian cancer stem cells the target for innovative immunotherapy?Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.
P2860
Q26749015-1B1DAEE3-6648-4D61-9508-C1C44518A0DFQ34044302-81E18D4A-1C86-4DCA-B1D5-6A74D44BA6B8Q35598557-CAB0A01D-D0A2-4328-A75B-E686CC470D65Q35822133-541045C7-1713-42DA-8BB2-FD897A3AEA91Q36962860-B4BEF243-70D7-4408-88AA-D5884F91E4CFQ37078999-3A437089-D7B8-4C44-A5E2-02E20480499DQ37301671-CB61B43C-90F7-4809-B118-0D2A77769AFDQ37559401-6D0904DF-87C9-4346-972D-F722D61FAB5FQ38685020-C019919A-73AC-407F-8F8C-20B5363650E0Q38741186-0EA030C6-2ABC-4FE9-B1CA-AD85AE7A4588Q38828829-933C9006-2825-4504-9FF2-DEA75D1CA15FQ39176046-2157B386-73AD-42BA-957A-B7D4E59FB37CQ39177087-010CEDE2-A5B6-412B-ACDD-695C8376F084Q39256918-05974831-D975-4390-AF38-4606812DFDECQ45918458-97A5F063-1C83-4663-8CB8-51EF96CBD2C6Q47770635-23CE44BB-B72D-4E53-8B75-0A99519BBDF0Q55164226-7F2F02DF-06F8-4B62-BC9D-E8EA1AE3E86EQ55316979-260310BD-3654-4989-A78A-A1B6CA20704A
P2860
Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Patient-derived glioblastoma s ...... the T cell aging marker CD57.
@en
type
label
Patient-derived glioblastoma s ...... the T cell aging marker CD57.
@en
prefLabel
Patient-derived glioblastoma s ...... the T cell aging marker CD57.
@en
P2093
P2860
P356
P1433
P1476
Patient-derived glioblastoma s ...... the T cell aging marker CD57.
@en
P2093
Elke Firat
Gabriele Niedermann
Michael Hettich
Shruthi Prasad
Simone Gaedicke
Xuekai Zhu
P2860
P304
P356
10.18632/ONCOTARGET.2767
P407
P577
2015-01-01T00:00:00Z